Clinical Trial Update: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) [Phase 1]

View source ↗

Summary

Phase 1 dose exploration study of birabresib (MK-8628) in selected advanced solid tumors (NMC, TNBC) was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nut Midline Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• birabresib (birabresib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Status: TERMINATED | Results posted: 2018-11-05